Showing 41 - 60 results of 112 for search '"rheumatology"', query time: 0.04s Refine Results
  1. 41
  2. 42
  3. 43

    Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort... by Raj Tummala, Richard A Furie, Laurent Arnaud, Eric F Morand, Martin Aringer, Stephanie Chen, Barnabas Desta, Alberta Hoi, Bo Ding, Christine Peschken, Jonatan Hedberg, Tina Grünfeld Eén, Alessandro Sorrentino, Danuta Kielar

    Published 2025-01-01
    “…In subgroup analyses, patients with high IFNGS and high disease activity state (HDAS) at baseline used more immunosuppressants and glucocorticoids compared with those with low IFNGS and non-HDAS at baseline.Conclusions These findings underscore that SLE therapy is still often unable to reach goals as recommended by the European Alliance of Associations for Rheumatology, both with regard to glucocorticoid use and disease activity, suggesting that there is an unmet need for new treatment options for patients with SLE.Trial registration number NCT03189875; 16 June 2017.…”
    Get full text
    Article
  4. 44
  5. 45
  6. 46
  7. 47
  8. 48

    Clinical Features and Prognosis of Double-Positive Anti-MDA5 and Anti-CCP Antibodies in Dermatomyositis: A Retrospective Study by Xu X, Zhu L, Li S, Wang G, Ge Y

    Published 2025-02-01
    “…Xiayu Xu,1 Longyang Zhu,2 Sizhao Li,3 Guochun Wang,3 Yongpeng Ge3 1Department of Rheumatology and Immunology, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province, People’s Republic of China; 2Peking University, China-Japan Friendship School of Clinical Medicine, Beijing, People’s Republic of China; 3Department of Rheumatology, The Key Laboratory of Myositis, China-Japan Friendship Hospital, Beijing, People’s Republic of ChinaCorrespondence: Yongpeng Ge, Department of Rheumatology, The Key Laboratory of Myositis, China-Japan Friendship Hospital, Beijing, 100029, People’s Republic of China, Email [email protected]: To investigate the clinical features and prognosis of anti-melanoma differentiation-related gene 5 (MDA5) antibody and anti-cyclic citrullinated peptide (CCP) antibody double-positive dermatomyositis (DM) (MDA5+/CCP+ DM).Methods: A retrospective analysis of 264 consecutive cases of MDA5+ DM hospitalized from March 2018 to March 2022, and patients with anti-CCP antibodies were screened out. …”
    Get full text
    Article
  9. 49
  10. 50
  11. 51
  12. 52
  13. 53
  14. 54
  15. 55
  16. 56
  17. 57
  18. 58
  19. 59
  20. 60

    Arteritis de células gigantes: actualización diagnóstica y terapéutica by Paloma Muñoz-Reinoso, Ana Domínguez-Mayoral, Francisco J. Toyos-Sáenz de Miera, Laura Castillo-Moreno, Sara Banda-Ramírez, José J. Pérez-Venegas

    Published 2024-10-01
    “…Se han tomado como referencia los protocolos diagnósticos y terapéuticos elaborados por el American College of Rheumatology y la European Alliance of Associations for Rheumatology. …”
    Get full text
    Article